Teduglutide (Revestive®) is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.
|NCPE Assessment Process||Ongoing|
|Rapid review received||13/03/2017|
|Rapid review completed||12/04/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
|Full pharmacoeconomic assessment commissioned by HSE||12/04/2017|
|Pre-submission consultation with Applicant||15/05/2017|
|Submission received from Applicant||31/07/2017|
|Preliminary review sent to Applicant||21/11/2017|
|NCPE assessment re-commenced||05/12/2017|
|Factual accuracy sent to Applicant||06/02/2018|
|NCPE assessment re-commenced||21/02/2018|
|NCPE assessment completed||16/03/2018|
|Full pharmacoeconomic assessment outcome||Reimbursement not recommended|
The HSE has approved reimbursement following confidential price negotiations January 2021.